Anti-Vascular Endothelial Growth Factor Therapeutics Market Report: Revenue Analysis, Growth, Trends, Forecast 2033
Posted by ramacharitbrc on February 6th, 2024
The Anti-Vascular Endothelial Growth Factor Therapeutics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Anti-Vascular Endothelial Growth Factor Therapeutics Market:
https://www.thebusinessresearchcompany.com/report/anti-vascular-endothelial-growth-factor-therapeutics-global-market-report
According to The Business Research Company’s Anti-Vascular Endothelial Growth Factor Therapeutics Global Market Report 2024, The anti-vascular endothelial growth factor therapeutics market size has grown marginally in recent years. It will grow from .18 billion in 2023 to .35 billion in 2024 at a compound annual growth rate (CAGR) of 1.3%. The growth in the historic period can be attributed to rise in age-related macular degeneration, increased incidence of diabetic retinopathy, advancements in retinal disease diagnosis, clinical success and efficacy, shift to outpatient treatment.
The anti-vascular endothelial growth factor therapeutics market size is expected to see marginal growth in the next few years. It will grow to .13 billion in 2028 at a compound annual growth rate (CAGR) of 1.5%. The growth in the forecast period can be attributed to aging population and ocular diseases, expanding applications in retinal disorders, development of next-generation therapeutics, increasing emphasis on early intervention, global health initiatives and access to treatment. Major trends in the forecast period include increasing utilization in cancer treatment, focus on combination therapies in ophthalmology, exploration of biosimilar versions, research on resistance mechanisms, integration with imaging technologies.
The increase in the prevalence of ophthalmic diseases is expected to propel the growth of the anti-vascular endothelial growth factor therapeutics market going forward. The prevalence of ophthalmic diseases refers to the number or proportion of individuals within a given population who have been diagnosed with or exhibit specific eye conditions or diseases. Anti-vascular endothelial growth factor (VEGF) therapeutics help reduce the prevalence of ophthalmic diseases by effectively treating ailments such as wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. For instance, in October 2022, according to World Health Organization, a Switzerland-based international public health organization, globally, around 2.2 billion people have near or distance vision impairment, and 1 billion people suffer from near or distance vision impairment. Further, among these, 88.4 million are suffering from refractive error, 94 million have cataracts, 8 million have age-related macular degeneration, and around 3.9 million have diabetic retinopathy. Therefore, the increase in the prevalence of ophthalmic diseases is driving the growth of the anti-vascular endothelial growth factor therapeutics market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10683&type=smp
The Anti-Vascular Endothelial Growth Factor Therapeutics Market Covered In This Report Is Segmented –
1) By Product: Eylea, Lucentis, Beovu
2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration
3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users
Advancements in therapeutics are a key trend gaining popularity in the anti-vascular endothelial growth factor therapeutics market. Companies operating in the anti-vascular endothelial growth factor therapeutics market are adopting advanced therapeutics to sustain their position in the market. For instance, in May 2022, Ashvattha Therapeutics Inc, a US-based clinical-stage biopharmaceutical company, released phase 1 safety data for healthy subjects for subcutaneous anti-VEGF wet AMD (age-related macular degeneration) and DME (diabetic macular edema) candidates. D-4517.2 therapy is a first-in-class therapy developed to address the unmet needs of DME conditions. D-4517.2 therapy is being developed for self-administration using an autoinjector. The autoinjector D-4517.2 enable patients to self-administer the medication once a month in the comfort of their home.
The Anti-Vascular Endothelial Growth Factor Therapeutics Market Report Table Of Contents Includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
………..
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
